File an IND for the ATRS-1902 endocrinology asset
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 5 Mar 2021
- Due
- 30 Jun 2021
- Delivered
- June 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“ATRS-1902: Endocrinology Asset Completed Pre-IND meeting with FDA Expected IND filing in 1H 2021”
What we found
Evidence strength A What the grades mean
Later filings state the IND for ATRS-1902 was submitted to the FDA in June 2021, within the 1H 2021 deadline. The FDA accepted it in July 2021.
-
A Antares Pharma, Inc. 10-K filed 2022-03-03
“In June 2021, we submitted an IND application with the FDA for the initiation of a Phase 1 clinical study of ATRS-1902 for adrenal crisis rescue.” ✓ confirmed on the page
-
A Antares Pharma, Inc. 10-Q filed 2021-08-05
“In June 2021, we submitted an IND application with the FDA for the initiation of a Phase 1 clinical study of ATRS-1902 for adrenal crisis rescue.” ✓ confirmed on the page
-
A Antares Pharma, Inc. 10-Q filed 2021-08-05
“We expect to file an IND for this program with the FDA in the second half of 2021.” ✓ confirmed on the page
Checked 27 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory filing
- Indicative materiality
- Medium rules
- Action
- File
- Deliverable
- IND filing for ATRS-1902 endocrinology asset
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Antares Pharma, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C016169-025252 · Corrections policy